• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study
ConclusionPoor adherence to NOACs is associated with increased risks of thromboembolism and all-cause mortality. The minimal adherence threshold should be ≥ 90%, preferably even ≥ 95%.
Source: Cardiovascular Drugs and Therapy - September 14, 2023 Category: Cardiology Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with those on VKAs. Irrespective of the type of oral anticoagulation therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - November 8, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
CONCLUSION: Guideline adherence on stroke prevention was higher in Belgium than in the rest of Europe, and increased over time. NOAC use in Belgium was the highest of Europe at the study start, with many countries catching up later. Possible reasons are discussed. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov . Unique identifier: NCT01090362. PMID: 30369290 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - October 31, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving NOACs and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with VKA. Irrespective of the type of OAC therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - March 12, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

NOACs only for those who cannot tolerate a VKA: where is the evidence?
Authors: Bhagirath VC, Cosyns B, Eikelboom JW Abstract The 2016 European Society of Cardiology Guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation. A recent report from the Belgian Healthcare Knowledge Centre (KCE) raised concerns about the results of the phase 3 randomised trials that led to the approval of the NOACs for this indication and concluded that NOACs should only be used for patients who fail or cannot undergo treatment with a vitamin K antagonist because they cannot achieve stable INR values. ...
Source: Acta Cardiologica - February 26, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research